Replimune shares rebounded Friday after an FDA advisory committee voted in favor of the company's RP1 melanoma therapy [1, 2].
The positive outcome from the panel increases the likelihood of accelerated approval for the treatment. This regulatory milestone is critical for the biotech company as it seeks to bring its lead therapy to the U.S. market to treat melanoma patients.
The stock recovery followed a multi-day decline earlier in the week [1]. In response to the committee's favorable vote, investment firm Cantor Fitzgerald upgraded the stock [1, 2].
Analysts said that the positive panel outcome improved the odds of the therapy receiving official approval [2]. The RP1 therapy is the lead candidate for Replimune, and the advisory committee's support serves as a primary indicator of the FDA's likely final decision.
Market participants are now awaiting the official regulatory ruling. The FDA decision is expected on Aug. 2 [2].
The surge in share price on Friday marked one of the strongest trading days in the company's history [2]. This movement reflects investor confidence that the regulatory path for RP1 has cleared a major hurdle, the advisory committee's review process.
“Replimune shares rebounded Friday after an FDA advisory committee voted in favor of the company's RP1 melanoma therapy.”
The FDA advisory committee's vote is a non-binding but highly influential signal. While the FDA is not required to follow the panel's recommendation, it typically does so in cases of clear consensus. A positive vote combined with an analyst upgrade from Cantor Fitzgerald suggests that the market now views the RP1 therapy as having a high probability of commercialization, which directly impacts the company's valuation ahead of the August 2 decision.
